Glaukos Announces Participation in Upcoming Investor Conferences
November 08 2024 - 7:00AM
Business Wire
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical
and medical technology company focused on novel therapies for the
treatment of glaucoma, corneal disorders and retinal diseases,
today announced that its management is scheduled to participate in
the following upcoming investor conferences:
- Stifel Healthcare Conference on Tuesday, November 19, 2024, at
12:40 p.m. ET in New York City, NY
- Stephens Annual Investment Conference on Wednesday, November
20, 2024, at 10:00 a.m. ET in Nashville, TN
- BTIG Ophthalmology Day on Monday, December 2, 2024, at 4:40
p.m. ET (Virtual)
- Piper Sandler Annual Healthcare Conference on Wednesday,
December 4, 2024, at 1:00 p.m. ET in New York City, NY
- Citi Global Healthcare Conference on Thursday, December 5,
2024, at 9:30 a.m. ET in Miami, FL
A live and archived webcast for these events, where applicable,
will be available in the Investors section of the Glaukos website
at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and
medical technology company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012. In 2024, Glaukos commenced commercial
launch activities for iDoseĀ® TR, a first-of-its-kind,
long-duration, intracameral procedural pharmaceutical designed to
deliver 24/7 glaucoma drug therapy inside the eye for extended
periods of time. Glaukos also markets the only FDA-approved corneal
cross-linking therapy utilizing a proprietary bio-activated
pharmaceutical for the treatment of keratoconus, a rare corneal
disorder. Glaukos continues to successfully develop and advance a
robust pipeline of novel, dropless platform technologies designed
to meaningfully advance the standard of care and improve outcomes
for patients suffering from chronic eye diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241108318039/en/
Chris Lewis Vice President, Investor Relations & Corporate
Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Nov 2023 to Nov 2024